HOME > TOP STORIES

TOP STORIES

ORGANIZATION RAD-AR Council Accelerating Initiative to Prepare Medication Guides in English toward Tokyo 2020 Olympic and Paralympic Games

February 6, 2020
ORGANIZATION Japan Red Cross Set to Push Formularies at All Group Hospitals, Despite Medical Fee Plan Dropped

February 5, 2020
BUSINESS Oncolys Hopes for Chugai’s Participation in US Development of Telomelysin: Chief

February 4, 2020
BUSINESS Opdivo Sales Drop 4.7% in April-December, but Ono Secures Higher Profits

February 3, 2020
BUSINESS Chugai Ups Core EPS CAGR Target to “Around 30%”: 3-Year Biz Plan

January 31, 2020
BUSINESS Chugai’s 2019 Earnings Renews Record for Third Year on Hemlibra, Tecentriq

January 31, 2020
REGULATORY Takeda’s RCC Drug Cabometyx Now in Line for March Approval; Alecensa, Rozlytrek Opdivo and More

January 30, 2020
REGULATORY Japan Ups Responses against Wuhan Coronavirus as First Domestic Transmission Confirmed

January 29, 2020
INTERVIEW “Excessive Self-Restraint” of Promotion Activities by Drug Makers Hindering Drugs’ Lifecycle Management: Physician

January 28, 2020
REGULATORY Discussions on Off-Year Re-Pricing to Begin in Spring, Focus on Scope of Drugs, Impact on Stakeholders: MHLW Bureau Chief

January 27, 2020
REGULATORY ICH’s Guidelines Helped Bring NDMA Contamination Problem to Light: NIHS Officials

January 24, 2020
REGULATORY Nasal Steroid Used as “Reference Drug” for Xolair in Special Re-Pricing

January 23, 2020
REGULATORY Get Serious about Reviewing Scope of Health Coverage, Says MOF Budget Examiner

January 22, 2020
REGULATORY Japan’s Special Re-Pricing Rules to Hit 17 Drugs in April; Potentially Big Slash for Keytruda, Lixiana

January 22, 2020
REGULATORY Xolair Faces New Special Re-Pricing Rule; Keytruda, Lixiana Caught by Huge-Seller Price Slash

January 21, 2020
BUSINESS Keytruda Snags Best-Seller Title in 2019 Drug Ranking: Encise

January 20, 2020
BUSINESS Xolair’s Use Would Be Limited to 1-3% of Pollen Allergy Patients in Japan: Specialist

January 20, 2020
REGULATORY MHLW Bureau Chief Says Delay Would Be Inevitable to Revise Drug Distribution Guidelines as Bid-Rigging Probe Continues

January 17, 2020
ACADEMIA Impact of Oligonucleotides - 1: Onpattro a Major Advance in FAP Treatment, but Challenges Remain

January 16, 2020
BUSINESS Tapped as Next Mitsubishi Tanabe Chief, Hiroaki Ueno Vows to Enrich Pipeline, Accelerate Global Biz

January 15, 2020

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo Backs Draft FY2026 Pricing Reform Outline, Rejects Key Industry Requests

By Takashi Ebisawa

The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…